CN103732588B - 螺环分子作为蛋白激酶抑制剂 - Google Patents

螺环分子作为蛋白激酶抑制剂 Download PDF

Info

Publication number
CN103732588B
CN103732588B CN201280037541.0A CN201280037541A CN103732588B CN 103732588 B CN103732588 B CN 103732588B CN 201280037541 A CN201280037541 A CN 201280037541A CN 103732588 B CN103732588 B CN 103732588B
Authority
CN
China
Prior art keywords
ring
membered
substituted
cancer
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280037541.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103732588A (zh
Inventor
王召印
李连海
王志刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Xinqi Biomedical Technology Co ltd
Original Assignee
NANJING AOZHAO BIOTECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NANJING AOZHAO BIOTECHNOLOGY Co Ltd filed Critical NANJING AOZHAO BIOTECHNOLOGY Co Ltd
Publication of CN103732588A publication Critical patent/CN103732588A/zh
Application granted granted Critical
Publication of CN103732588B publication Critical patent/CN103732588B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280037541.0A 2011-07-27 2012-07-26 螺环分子作为蛋白激酶抑制剂 Expired - Fee Related CN103732588B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161457980P 2011-07-27 2011-07-27
US61/457,980 2011-07-27
PCT/CA2012/000709 WO2013013308A1 (en) 2011-07-27 2012-07-26 Spirocyclic molecules as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CN103732588A CN103732588A (zh) 2014-04-16
CN103732588B true CN103732588B (zh) 2016-10-12

Family

ID=47600420

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280037541.0A Expired - Fee Related CN103732588B (zh) 2011-07-27 2012-07-26 螺环分子作为蛋白激酶抑制剂

Country Status (6)

Country Link
US (1) US9226923B2 (https=)
EP (1) EP2739617A4 (https=)
JP (1) JP6062432B2 (https=)
CN (1) CN103732588B (https=)
CA (1) CA2842841C (https=)
WO (1) WO2013013308A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048507A1 (en) * 2013-09-26 2015-04-02 Mnemosyne Pharmaceuticals, Inc. Selective octahydro-cyclopenta[c] pyrrole negative modulators of nr2b
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220079921A (ko) 2019-10-09 2022-06-14 노파르티스 아게 M4 작용제로서의 2-아자스피로[3.4]옥탄 유도체
PE20221454A1 (es) 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
CA2517256C (en) * 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
ME01309B (me) * 2004-08-26 2013-12-20 Pfizer Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza
BRPI0514687A (pt) * 2004-08-26 2008-06-17 Pfizer compostos amino heteroarila como inibidores de proteìna tirosina cinase
ES2336625T3 (es) * 2006-03-22 2010-04-14 Vertex Pharmaceuticals Incorporated Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
ATE523508T1 (de) * 2007-10-25 2011-09-15 Astrazeneca Ab Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
WO2009099982A1 (en) * 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
BRPI1010974A2 (pt) * 2009-05-22 2019-09-24 Exelixis Inc benzoxazepinas baseada em inibidores p13k/ m tor contra doenças proliferativas
CN101851237B (zh) * 2010-06-18 2012-10-17 南方医科大学 一种螺环化合物及其制备方法和应用
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use

Also Published As

Publication number Publication date
CA2842841C (en) 2016-04-19
CA2842841A1 (en) 2013-01-31
WO2013013308A1 (en) 2013-01-31
EP2739617A4 (en) 2015-01-28
JP6062432B2 (ja) 2017-01-18
EP2739617A1 (en) 2014-06-11
CN103732588A (zh) 2014-04-16
US20140243303A1 (en) 2014-08-28
US9226923B2 (en) 2016-01-05
JP2014521609A (ja) 2014-08-28

Similar Documents

Publication Publication Date Title
US12398146B2 (en) Heterobicyclic amides as inhibitors of CD38
CN104080789B (zh) 作为布鲁顿酪氨酸激酶抑制剂的环状分子
US9650358B2 (en) Pyridine CDK9 kinase inhibitors
CN103732588B (zh) 螺环分子作为蛋白激酶抑制剂
CN101573358B (zh) 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
KR102779702B1 (ko) 브루톤 티로신 키나아제 억제제로서의 고리형 분자
CN104039797B (zh) 作为细胞凋亡诱导剂的杂环分子

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190809

Address after: 510530 Room 1101, 1936 Kaichuang Avenue, Huangpu District, Guangzhou City, Guangdong Province

Patentee after: Guangdong Xinqi Biomedical Technology Co.,Ltd.

Address before: Guanghua Road, Baixia District Nanjing city Jiangsu province 210014 Yongfeng Road No. 1 Baixia High-tech Industrial Park No. 8 Building 503 room B

Patentee before: BETA PHARMA CANADA Inc.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161012

Termination date: 20210726

CF01 Termination of patent right due to non-payment of annual fee